The tumor immune environment has a strong prognostic value suggesting its role in the disease control, but is highly heterogeneous among patients. Origin of such heterogeneity is not fully understood and it has been assumed that it could be driven by diversity of carcinogen exposure (tobacco, pollution) and/or by viral or bacterial infection, to each individual immune system characteristics and to the tumor cell diversity. Our major goal is to decipher cellular and molecular mechanisms related to host and environmental factors that impacts tumor as well as immune cells.
We develop translational research using various advanced and high throuput precision technologies (multiplex immunohistochemistry and flow cytometry, scRNAseq and nanostring techniques, NGS, WES), combined with large-scale bioinformatics analyses. We use large cohorts of lung tumor bearing patients followed up in oncology and surgery department of Cochin hospital and enrolled in clinical trials, including immunotherapy. We address mechanistic questions in murine models of spontaneous and orthotopic lung tumors and in organoids developed from human tumors.
Main projects developed in this theme
– Characterization of innate immune cell functions (Natural Killer cells and neutrophils) in the tumor microenvironment in patients with a concomitant COPD (Pr Isabelle Cremer, Pr Diane Damotte)
– Understanding the interactions of respiratory viral infection (influenza virus, Respiratory Syncytial Virus and Coronavirus) with the tumor immune microenvironment and its impact on tumor progression (Pr Isabelle Cremer, Pr Marco Alifano, Dr Pierre-Emmanuel Joubert)
– Study of the role of the fitness of the patients and its nutritional status on metabolic reprogramming inflammation and on the tumor microenvironment with a particular focus on immune responses (Pr Marco Alifano, Dr Pierre-Emmanuel Joubert)
– Study on the mutational status of tumor cells and its link to anti-tumoral immune responses and response to immunotherapy (Pr Diane Damotte and Dr Audrey Lupo)
– Innovative clinical trials using immunotherapy strategies and finding of biomarkers of response to treatments (Pr Marie Wislez and Pr Karen Leroy)
– Understanding the role of memory B cells and autoantibodies in immune-related cardiotoxocity following anti-checkpoint mAbs treatment in cancer patients (Dr Sophie Sibéril, Pr Diane Damotte)
Permanent Members
Isabelle Cremer (PU immunologie, Sorbonne Université)
Pierre-Emmanuel Joubert (MCU immunologie, Sorbonne Université)
Sophie Sibéril (MCU immunologie, Sorbonne Université)
Marco Alifano (PU-PH, chef du service de chirurgie thoracique, Hôpital Cochin)
Diane Damotte (PU-PH, anatomo-pathologiste, Hôpital Cochin)
Karen Leroy (PU-PH, biologiste, Hôpital Cochin)
Audrey Lupo (MCU-PH, anatomo-pathologiste, Hôpital Cochin)
Marie Wislez (PU-PH, pneumo-oncologist, Hôpital Cochin)
Solenne Marmier (IE, Sorbonne Université)
Nathalie Josseaume (TechR, Sorbonne Université)
Pubmed key
Cremer I OR Damotte D OR Alifano M OR Sibéril S OR Joubert PE OR Wislez M
Keywords
Tumor microenvironment, viral infection, immunotherapy, immune related toxicity, biomarkers
Researchers info
Isabelle CREMER
Orcid: 0000-0002-0963-1031
Twitter : @CremerIsabelle
Diane DAMOTTE
Orcid: 0000-0001-5355-3045
Twitter : @DianeDamotte
Marie WISLEZ
Orcid: 0000-0001-7518-7859
Twitter : @MarieWislez
Marco ALIFANO
Orcid: 0000-0001-7518-7859
Twitter : @AlifanoMarco
Karen LEROY
Orcid: 0000-0002-4379-0140
Audrey LUPO
Orcid: 0000-0002-7196-2114
Sophie SIBERIL
Orcid : 0000-0003-0184-2886
Pierre-Emmanuel JOUBERT
Orcid : 0000-0001-9859-6479